<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19421" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Migraine Headache in Childhood</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Khalili</surname>
            <given-names>Yasir</given-names>
          </name>
          <aff>Virginia Commonwealth University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Asuncion</surname>
            <given-names>Ria Monica D.</given-names>
          </name>
          <aff>University of Santo Tomas, Medicine and Surgery</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chopra</surname>
            <given-names>Pooja</given-names>
          </name>
          <aff>MD Anderson</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasir Al Khalili declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ria Monica Asuncion declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pooja Chopra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19421.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Migraine is the most frequent primary headache disorder in children and adolescents. Up to 18% of patients in the pediatric emergency room are found to be migraine-related. The diagnosis of migraine in children and adolescents remains a clinical diagnosis. Acute treatment recommendations for children include using over-the-counter analgesics and triptan medications approved by the US Food and Drug Administration. Preventive treatment strategies involve lifestyle modifications, behavioral approaches, and consideration of preventive medications with the lowest side effect profiles. This activity reviews the evaluation and treatment of pediatric migraine and highlights the role of the interprofessional team in evaluating and treating children with migraine.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathophysiology of migraines in children.</p></list-item><list-item><p>Review the importance of physical exams in assessing pediatric migraines and to help rule out other conditions.</p></list-item><list-item><p>Outline the management options for pediatric migraine that are currently available.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance the management of pediatric migraine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19421&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19421">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19421.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Migraine and headache disorders are among the leading causes of disability and morbidity worldwide.<xref ref-type="bibr" rid="article-19421.r1">[1]</xref> Migraine is the most frequent primary headache disorder in children and adolescents.&#x000a0;About 1 in 10 children experience recurrent headaches due to migraine, which can significantly impair school performance and quality of life.<xref ref-type="bibr" rid="article-19421.r2">[2]</xref></p>
        <p>Up to 18% of patients in the pediatric emergency room are found to be migraine-related.<xref ref-type="bibr" rid="article-19421.r3">[3]</xref>&#x000a0;However, migraine in children differs from that in adults because it is often associated with other symptoms, not only headache. Migraine in children also manifests conditions like cyclic vomiting and abdominal migraine, wherein children are usually considered to have gastrointestinal tract disorder.<xref ref-type="bibr" rid="article-19421.r4">[4]</xref></p>
        <p>The diagnosis of migraine in children and adolescents remains a clinical diagnosis. The clinician must obtain a detailed and comprehensive headache history that focuses on the location, quality, severity, and duration of the pain.&#x000a0;Nonetheless, complicated migraine is often associated with focal neurological symptoms such as ataxia, hemiparesis, or altered level of consciousness that concerns the examining clinician. Some episodic syndromes may show ambiguity, such as migraine triggered by trauma.<xref ref-type="bibr" rid="article-19421.r4">[4]</xref></p>
        <p>Acute treatment recommendations for children include using over-the-counter analgesics and triptan medications approved by the US Food and Drug Administration. Preventive treatment strategies involve lifestyle modifications, behavioral approaches, and consideration of preventive medications with the lowest side effect profiles.<xref ref-type="bibr" rid="article-19421.r5">[5]</xref>&#x000a0;There are evidence-based recommendations for the acute symptomatic treatment of migraine in children, which support the efficacy of using ibuprofen, acetaminophen, and triptans. However, no acute treatments were effective for migraine-related nausea or vomiting; some triptans were effective for migraine-related phonophobia and photophobia. Recommendations focus on the significance of early treatment, selecting the most suitable route of administration in relation to the characteristics of the migraine attack, and offering counseling assistance regarding lifestyle modification to prevent exacerbation of migraines, such as trigger avoidance and medication overuse.<xref ref-type="bibr" rid="article-19421.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-19421.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Migraine is a primary headache disorder and a common, recurrent, disabling condition affecting an estimated 18% of women and 6% of men. There are commonly reported triggers that can induce migraine, namely stress, fatigue, various foods, alcohol, drugs, smoking, weather changes, and odors. Recent studies also provide new insights into the underlying pathophysiology and genetics of migraine that would provide novel pharmacotherapies for management and prevention.<xref ref-type="bibr" rid="article-19421.r7">[7]</xref>&#x000a0;</p>
        <p>Children with migraine have a genetic predisposition activated by an environmental or physiological stimulus.&#x000a0;These stimuli include exposure to drugs, diet, stress, or puberty. Most children with a history of migraines seem to have a positive family history.<xref ref-type="bibr" rid="article-19421.r8">[8]</xref> Some studies have shown genetic contributions.<xref ref-type="bibr" rid="article-19421.r9">[9]</xref> However, it is not fully proven yet. Genetic etiology is certain for certain types of migraines, such as hemiplegic migraine. Mutations have been reported in&#x000a0;<italic toggle="yes">CACNA1A</italic> (calcium channel), <italic toggle="yes">ATP1A2</italic> (Na/K-ATPase), and <italic toggle="yes">SCN1A</italic> (sodium channel) genes resulting in the development of hemiplegic migraine.</p>
        <p>Migraine is considered a strongly heritable disorder. Studies investigated the age of onset of migraine between successive generations. The age of migraine onset was significantly lower in the children with a history of maternal or paternal migraine than in their parents. Findings revealed that parental history of migraine showed that children with migraine were significantly younger at the first appearance of migraine than their affected parents.<xref ref-type="bibr" rid="article-19421.r10">[10]</xref>&#x000a0;Migraine is perceived to affect the relationship between the parent and child. A parent with migraines increases a child's risk of having a more severe migraine disease. However, children with migraine whose parent also has migraine seem to receive more early and aggressive treatment. The effect of migraine goes beyond the parent with migraine and influences children across biological, psychological, and social domains.<xref ref-type="bibr" rid="article-19421.r10">[10]</xref></p>
      </sec>
      <sec id="article-19421.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Migraine is one of the most burdensome primary headache disorders in the pediatric population.<xref ref-type="bibr" rid="article-19421.r11">[11]</xref> Epidemiologic data can help us to understand its scope and distribution. Knowing the sociodemographic and environmental risk factors usually helps us to know which groups are at risk of migraine.&#x000a0;Prevalence ranges from 5% to 40% in the pediatric population.&#x000a0;In the United States, migraine is diagnosed in 5% of children by age 10, with an estimated prevalence rate of 10%.<xref ref-type="bibr" rid="article-19421.r12">[12]</xref>&#x000a0;</p>
        <p>The prevalence increases with age and reaches 80% at the time they transfer to adult neurologic care. Before puberty, no sex differences exist, but in later adolescence, females predominate.<xref ref-type="bibr" rid="article-19421.r13">[13]</xref>&#x000a0;Another study showed that&#x000a0;migraine prevalence estimates vary from 1% to 3% at seven years and 4% to 11% at 7 to 15 years. Before puberty, there is an equal prevalence in girls and boys, but after puberty, the prevalence is 2 to 3 times more common in girls.<xref ref-type="bibr" rid="article-19421.r14">[14]</xref></p>
        <p>Data from &#x0223c;1.2 million children and adolescents in Germany revealed that the incidence of migraine increased with age, reaching about 1% per year around the age of 10 for both sexes, 3.49% per year in females, and 1.72% per year in males at the age of 19. Incidences in males and females were the same until 13 years of age but higher in females.<xref ref-type="bibr" rid="article-19421.r7">[7]</xref>&#x000a0;</p>
        <p>Pooled data&#x000a0;from China, Japan, and South Korea revealed that the overall prevalence of migraine increased with age. There were reports on the significant association of migraine with high levels of disability and negative effects on quality of life. Studies suggested low levels of disease awareness/diagnosis within each country studied. Moreover, findings showed that over-the-counter medication use was high and prescription medication use was low in each country, which suggested that there are unmet needs for migraine in terms of sufficient and appropriate diagnosis and better management and therapies for the treatment of migraine in East Asia. There is also a need to conduct population-based studies assessing disease burden and clinical management of migraine to confirm unmet needs for migraine across East Asia.<xref ref-type="bibr" rid="article-19421.r15">[15]</xref></p>
        <p>Migraine in children below seven years of age is challenging for clinicians. As there are only a few studies in this age group, what we have shows migraine in this age group&#x000a0;affects up to 4% of the general population. This is most likely underestimated due to the lack of specific diagnostic markers, the frequent difficulty of describing pain in childhood, and the necessity of reliable parental reports. Recent findings showed that migraine has some differences, especially in clinical and therapeutic terms, in this age group compared to subsequent ages. Current literature also showed that the onset of migraine in younger children might play an unfavorable role in its natural history; therefore, early identification and management of migraine is vital to the point of considering the factors of prenatal and perinatal development in the predisposition and anticipation of migraine onset.<xref ref-type="bibr" rid="article-19421.r16">[16]</xref></p>
        <p>A study for the association between preterm categories and migraine in Finland&#x000a0;revealed no evidence for a greater risk of migraine among individuals born preterm. Migraine was predicted by parental migraine, lower socioeconomic position, maternal hypertensive disorder, and maternal smoking during pregnancy.<xref ref-type="bibr" rid="article-19421.r17">[17]</xref>&#x000a0;</p>
        <p>Migraine and epilepsy comorbidity is also being studied since they represent prevalent chronic childhood neurological disorders. Both diseases rely on the common pathophysiologic and genetic mechanisms of paroxysmal disorders, the similarity of their precipitating factors, clinical manifestations, and therapeutic approaches. Numerous genetic diseases accompanied by migraine and epilepsy could lean towards the shared pathogenetic mechanisms of these paroxysmal disorders in which genetically determined channelopathies may play a vital part. The efficacy of antiepileptic drugs has been proven as the prophylactic treatment of migraine in pediatric patients as well as the advantages of levetiracetam as the prophylactic treatment for migraine and epilepsy comorbidity in children.<xref ref-type="bibr" rid="article-19421.r18">[18]</xref></p>
        <p>Another study evaluated the prevalence of headache subtypes, epilepsy, atopic disorders, motion sickness, and recurrent abdominal pain among ADHD children and their parents. Findings showed that migraines were significantly common among children with ADHD and their mothers. This means that migraine is a vital part of ADHD comorbidity, not only for children but also for mothers.<xref ref-type="bibr" rid="article-19421.r19">[19]</xref>&#x000a0;Another study perceived that the security of attachment to the mother and the father mediated the association between migraine and anxiety and concluded that insecure parental attachment might exacerbate anxiety in children with migraine and points to the importance of multimodal interventions, especially family relationships.<xref ref-type="bibr" rid="article-19421.r20">[20]</xref></p>
        <p>Other migraine comorbidities are atopic disorders such as allergic rhinitis, allergic rhinoconjunctivitis, and seasonal allergic rhinitis, as well as the disability caused by headache (ISAAC - International Study of Asthma and Allergies in Childhood; CARATkids - Control of Allergic Rhinitis and Asthma Test for Children; PedMIDAS - Pediatric Migraine Disability Assessment). Results showed higher scores on the PedMIDAS than those patients without atopy for children with current allergic rhinoconjunctivitis. There was also a significant positive correlation between CARATkids scores and PedMIDAS scores. Therefore, allergic rhinoconjunctivitis is correlated to enhanced disability caused by headaches among children with migraine.<xref ref-type="bibr" rid="article-19421.r21">[21]</xref>&#x000a0;</p>
        <p>Migraine was observed in 29% of 96 patients with sarcoidosis in another study. Among those with sarcoidosis, only the female sex was predictive of having migraine. There was no association between migraine and age, depression, dyspnea, immunosuppression use, or ESR.<xref ref-type="bibr" rid="article-19421.r22">[22]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-19421.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Migraine is now considered a brain disease. In the past, it was thought of as a vascular disease. This new theory requires the brain to be genetically sensitive to migraine-inducing neurochemical changes that result in premonitory symptoms.</p>
        <p>Migraine consists of trigeminal vascular system activation wherein nociceptive neurons that innervate the dura release various vasoactive peptides, including the most active calcitonin gene-related peptide.<xref ref-type="bibr" rid="article-19421.r16">[16]</xref>&#x000a0;These neurochemical changes lead to trigeminovascular activation and, eventually, neurogenic inflammation.<xref ref-type="bibr" rid="article-19421.r23">[23]</xref> This inflammation drops the threshold for trigeminal input entering the nucleus caudalis of the trigeminal nerve in the brain stem. These sensory changes from C1 and C2 dermatomes eventually synapse in the somatosensory and limbic cortices where conscious awareness of headache occurs.<xref ref-type="bibr" rid="article-19421.r24">[24]</xref><xref ref-type="bibr" rid="article-19421.r25">[25]</xref>&#x000a0;</p>
        <p>The possible reason why children have more severe and cyclic vomiting compared to adults is related to their reduced cholinergic function. Centrally, the area postrema&#x000a0;is considered the trigger zone and responds to circulating neuronal&#x000a0;and chemical emetic stimuli. Peripherally, vagal pathways are involved in emetic stimulation. The act of emesis is coordinated via abdominal vagal nerve afferents that terminate in the tractus solitaries nucleus. Signals are mediated by multiple cholinergic and adrenergic neurotransmitters, mainly 5-HT, 5-hydroxytryptamine, which binds to the 5-HT3 receptor, and substance P (SP), which binds to the neurokinin-1 receptor.</p>
        <p>Copeptin is a hypothalamic stress hormone synthesized in the hypothalamus with arginine-vasopressin and circulated from the neurohypophysis in equimolar amounts and can indicate the individual stress level. Studies revealed that copeptin levels were significantly higher in patients with childhood migraine. The specificity and sensitivity of copeptin for 249.5 pg/dL cut-off value predicting the diagnosis of migraine were 67% and 64%, respectively. Plasma copeptin levels tend to increase in childhood migraine due to increased oxidative stress.<xref ref-type="bibr" rid="article-19421.r26">[26]</xref>&#x000a0;&#x000a0;</p>
        <p>In line with an imbalance in cortical excitability, GABA-edited Magnetic resonance spectroscopy (MRS) studies revealed children (7&#x000a0;to 13 years) with migraine and aura had significantly lower glutamate levels in the visual cortex. Also, higher GABA levels were correlated to a higher migraine burden and higher glutamate in the thalamus. Higher GABA/Glx ratios in the sensorimotor cortex were related to longer migraine attacks. Lower GABA levels in the sensorimotor cortex were connected with being closer to their next migraine attack. Overall, this implied that GABA and glutamate disturbances occur early in migraine pathophysiology and emphasizes that adult migraine cannot be immediately correlated with pediatric patients.<xref ref-type="bibr" rid="article-19421.r27">[27]</xref></p>
        <p>The most common comorbidity with migraine in childhood is sleep disorders. There is a greater prevalence of parasomnias, obstructive sleep apnea, and sleep-related movement disorders in children migraineurs. This can be attributed to the bidirectional relationship between migraine and sleep disorders based on their shared pathophysiology. The structures and networks of the cerebral and neurochemical systems involved in migraine are closely related to those structures responsible for sleep regulation, particularly adenosine, melatonin, orexin, and calcitonin gene-related peptides.<xref ref-type="bibr" rid="article-19421.r16">[16]</xref>&#x000a0;A study evaluated the potential correlation between migraine and sleep disorders in children, as reflected by sleep architecture and electroencephalographic patterns. All children had inpatient full-night polysomnographic recordings. Those in the migraine group had decreased REM sleep, increased N1 sleep percentages, more arousal, and lower sleep latency, thereby establishing the significant relationship between migraine and sleep disorders using polysomnography.<xref ref-type="bibr" rid="article-19421.r28">[28]</xref></p>
        <p>The function of the insula, the hypothalamic-pituitary-adrenal axis, the serotonergic system, and the unstable hyperactivated neural networks may trigger the pathophysiology of both migraine and its psychiatric comorbidities. It is unclear whether the symptoms of anxiety and depression are comorbid with migraine in children due to the overlap between migraine symptomatology and that assessed by many screening tools. However, functional neurologic disorders such as psychogenic non-epileptic seizures (PNES) and other functional movement disorders are not common but can be comorbid with migraine in children and tend to improve with migraine treatment. A study revealed that a child's exposure to adverse childhood experiences (ACEs) appears to be near-linearly associated with the risk of migraine but not with tension-type headaches (TTH). The findings stressed the importance of choosing the appropriate screening methodologies for identifying psychiatric disorders in children with migraine.<xref ref-type="bibr" rid="article-19421.r29">[29]</xref>&#x000a0;</p>
        <p>An evaluation of hypertension in children with migraine by performing ambulatory blood pressure monitoring (ABPM) showed that although the frequency of hypertension was not higher, abnormal ABPM patterns were significantly more frequent in the migraine group (migraine, 45.9%; control, 16.7%; p, 0.018). At the same time, nighttime means arterial blood pressure, nighttime diastolic blood pressure, and the non-dipping pattern was greater in children with migraine than those in the control group (p &#x0003c; 0.05).<xref ref-type="bibr" rid="article-19421.r30">[30]</xref>&#x000a0;</p>
        <p>Some studies evaluated the clinical interdependency of myofascial trigger points and migraine in children, which would support an interaction of spinal and trigeminal afferents in the trigeminal-cervical complex as a contributing factor in migraine. Trapezius muscle trigger points were determined by palpation, and the threshold of pressure pain at the trigger points was obtained. Findings revealed an association between trapezius muscle myofascial trigger points and migraine but in children, it can be induced by pressure to myofascial trigger points, but not by pressure to non-trigger points in the trapezius muscle. Therefore, this supports the involvement of the trigeminal-cervical-complex in the pathophysiology of migraine, which might have implications for innovative treatment.<xref ref-type="bibr" rid="article-19421.r31">[31]</xref></p>
      </sec>
      <sec id="article-19421.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common symptom in children is headache; therefore, the importance of a detailed history and a thorough physical examination is vital in making the diagnosis.<xref ref-type="bibr" rid="article-19421.r2">[2]</xref>&#x000a0;The patient must have at least five attacks that fulfill the criteria of migraine, which include duration of at least an hour to 72 hours, unilateral location, pulsating quality, moderate to severe in intensity, aggravated by activity, and at least&#x000a0;one of the following: nausea and/or vomiting&#x000a0;or photophobia and photophobia.</p>
        <p>There is a slight difference in migraine among children compared to adults because the latter is mainly frontal rather than temporal/occipital and bilateral rather than unilateral.<xref ref-type="bibr" rid="article-19421.r32">[32]</xref></p>
        <p>A thorough physical examination is needed, including blood pressure measurement and palpation of the head in search of sinus tenderness and nuchal rigidity. A funduscopic examination is necessary to look for papilledema, hemorrhage, or other signs of increased intracranial pressure. A visual field examination should be done.<xref ref-type="bibr" rid="article-19421.r33">[33]</xref> Head circumference also is a must despite the age of the child. Examine the skin for any neurocutaneous finding that could indicate possible neurofibromatosis and tuberous sclerosis, which are highly associated with resulting intracranial neoplasms and headaches. Vomiting is more prominent in the pediatric migraine population. A study by Barlow showed recurrent vomiting during their first two years in toddlers before migraine headaches start and other associated migraine symptoms. It is essential to administer&#x000a0;the standard International Headache Society (IHS) questionnaire routinely&#x000a0;for the child and the parents to complete.<xref ref-type="bibr" rid="article-19421.r34">[34]</xref></p>
      </sec>
      <sec id="article-19421.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>While the diagnosis of pediatric migraine is primarily clinical, lab testing and neuroimaging may be needed in certain circumstances.</p>
        <p>
<bold>Indications for Lab Testing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Children with sickle cell disease may present with headaches in case of low Hgb. Blood work may be warranted for such patients.<xref ref-type="bibr" rid="article-19421.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>A lumbar puncture may be performed if an inflammatory process or mitochondriopathy is considered the cause of the headache. Caution is advised while performing lumbar punctures as it can worsen the headaches by causing intracranial hypotension.<xref ref-type="bibr" rid="article-19421.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>EEG may be performed in patients if there is clinical suspicion of seizures.&#x000a0;Migraine-associated EEG abnormalities are relatively common: 10% to 75% in total (paroxysmal in 20% to 30%).<xref ref-type="bibr" rid="article-19421.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Neuroimaging for Patients with Migraine Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Any neurological deficits, including but not limited to seizures, reduced visual acuity, altered consciousness, and deterioration of motor skills.</p>
          </list-item>
          <list-item>
            <p>Enlarged head in an infant or toddler.</p>
          </list-item>
          <list-item>
            <p>Abnormal ophthalmological evaluation, such as visual field cuts, disconjugate gaze, or abnormal fundus</p>
          </list-item>
          <list-item>
            <p>Headaches that always occur on one side (fixed unilaterally).</p>
          </list-item>
          <list-item>
            <p>Refractory headaches that last several days and are not responsive to treatment.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19421.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Migraine treatment is warranted in children if the headaches prevent the child from going through daily activities like going to school, playing, etc.</p>
        <p>Since migraine is prevalent in children and impacts the cause of their disability, effective treatment is likely to result in improved outcomes. Previous studies suggested that a biopsychosocial approach that applies interdisciplinary multimodal care is most effective for treating pediatric migraines. Key elements are as follows: (1) effective and timely acute pharmacological interventions (such as NSAIDs and/or triptans), (2) education of patients regarding self-management techniques, and (3) psychological interventions such as biofeedback, relaxation, and cognitive-behavioral therapy.<xref ref-type="bibr" rid="article-19421.r38">[38]</xref></p>
        <p>The treatment regimen can be both non-pharmacologic and pharmacologic. Non-pharmacologic measures include sleep hygiene patterns, diet, managing stress, exercise, and avoiding triggers. On the other hand, Pharmacologic treatment includes beta-blockers, calcium channel antagonists, serotonin antagonists, antidepressants, and antiepileptics.<xref ref-type="bibr" rid="article-19421.r32">[32]</xref></p>
        <p>Amitriptyline manifested a suitable effect on controlling headaches as well as adverse side effects. At the same time, nutraceuticals are found to be promising as effective drugs with fewer side effects. Coenzyme Q10 was observed to have promising therapeutic effects, especially in long-term use, with fewer side effects; however, amitriptyline presented a more rapid response.<xref ref-type="bibr" rid="article-19421.r39">[39]</xref></p>
        <p>Moreover, observational studies, randomized controlled trials, systematic reviews, and meta-analyses showed the efficacy and safety of single-compound nutraceuticals for managing migraine in children. The following nutraceuticals were reviewed: vitamin D, riboflavin, coenzyme Q10, magnesium, butterbur, and polyunsaturated fatty acids. However, due to low-quality evidence and limited studies, there were no definite conclusions on the efficacy of nutraceuticals for treating pediatric migraine.<xref ref-type="bibr" rid="article-19421.r40">[40]</xref></p>
        <p>Prophylaxis should be considered when migraine symptoms cause frequent school absenteeism, poor quality of life, recurring emergency room visits, and frequent analgesic use. Since the majority of the patients can be treated with lifestyle changes and acute attack prophylaxis, a study was conducted to compare the efficacy and side effects of drugs used in migraine prophylaxis, such as propranolol, topiramate, flunarizine, and cyproheptadine. There was a significant improvement in all drug groups, but topiramate was found to be the most effective drug in reducing the frequency of attacks. All four drugs in this study may be utilized for migraine prophylaxis in terms of effectiveness and safety, with palpitations as the most common side effect.<xref ref-type="bibr" rid="article-19421.r41">[41]</xref>&#x000a0;</p>
        <p>Triptans plus non-steroidal anti-inflammatory drugs (NSAIDs) reinforce triptan's effectiveness. lmotriptan and rizatriptan are effective as oral formulations. Meanwhile, sumatriptan and zolmitriptan are effective as both oral and nasal spray formulations. There are suggestions for considering dopamine receptor antagonists in cases of severe migraines.<xref ref-type="bibr" rid="article-19421.r42">[42]</xref>&#x000a0;A study evaluated the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headaches in patients from 6 to 11 years. Though the effect of high-dose ZNS on the primary endpoint of pain-free status at 2 hours was not statistically significant, ZNS was safe and well tolerated in this pediatric population.<xref ref-type="bibr" rid="article-19421.r43">[43]</xref>&#x000a0;In addition, ZNS is rapidly absorbed from the nasal mucosa and can be contributed to the fast onset of action. ZNS with a 5 mg dose was more effective in relieving headache pain, photophobia, and phonophobia and was associated with a&#x000a0;more rapid return to normal daily activities. Findings showed that ZNS was generally well tolerated, with no serious adverse events, and may benefit patients with nausea or who cannot easily swallow tablets.<xref ref-type="bibr" rid="article-19421.r44">[44]</xref>&#x000a0;</p>
        <p>On the other hand, another study revealed that sumatriptan and zolmitriptan nasal spray are above placebo in the two efficacy outcomes, but almotriptan, rizatriptan, sumatriptan with naproxen sodium, ibuprofen, and ibuprofen suspension were on top of placebo only in one of the efficacy outcomes. In addition, the findings showed that the best treatments for achieving pain-free effects are ibuprofen suspension, ibuprofen, and rizatriptan. In conclusion, most triptans and NSAIDs are effective in terms of pain-free or pain-relief. The most effective for pain-free is sumatriptan with naproxen sodium, while for pain relief, the most effective are ibuprofen and ibuprofen suspension.<xref ref-type="bibr" rid="article-19421.r45">[45]</xref>&#x000a0;This was supported by other evidence from small trials, which showed that ibuprofen improved pain freedom for the acute treatment of children with migraines. In general, triptans are also associated with higher rates of minimal adverse events.<xref ref-type="bibr" rid="article-19421.r46">[46]</xref></p>
        <p>Topiramate (TPM) decreases the frequency of headaches, and studies revealed that topiramate is effective and safe for migraine prophylaxis among children. The following are observed after TPM treatment: reduction in headache frequency, severity, and duration.<xref ref-type="bibr" rid="article-19421.r47">[47]</xref>&#x000a0;</p>
        <p>Prophylactic vitamin B12 therapy is used on migraine patients in adults, but limited studies were done regarding vitamin B12 and folic acid levels in pediatric patients diagnosed with migraine. Data showed a statistically significant difference between migraine patients and the control group regarding vitamin B12 and folic acid levels. The results indicated the requirement for routine evaluation of vitamin B12 and folic acid levels in pediatric patients diagnosed with migraine.<xref ref-type="bibr" rid="article-19421.r48">[48]</xref>&#x000a0;</p>
        <p>
<bold>Strategies for Migraine Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Counsel patients about the possible trigger factors and subsequent avoidance. Maintaining a headache diary may help identify such triggers.</p>
          </list-item>
          <list-item>
            <p>Relaxation and biofeedback techniques with counseling about diet and proper sleep</p>
          </list-item>
          <list-item>
            <p>Analgesics for intermittent headaches</p>
          </list-item>
          <list-item>
            <p>Antinausea agents such as promethazine and metoclopramide</p>
          </list-item>
          <list-item>
            <p>Prophylaxis with a daily preventive medication</p>
          </list-item>
        </list>
        <p>
<bold>Recommended Abortive Treatment</bold>
</p>
        <p>Abortive treatment may be required for children with migraine headache attacks. In a study conducted in Israel, about 87.5% of children, during the first recorded migraine attack, reported intake of only one type of medication for each headache episode, particularly ibuprofen or acetaminophen, and less than 25% used dipyrone (metamizole). After 2 hours of treatment, the rate of improvement was 65.4% &#x000b1; 27 for ibuprofen, 59.8 &#x000b1; 35.3 for acetaminophen, and 50.9 &#x000b1; 27.4 for dipyrone without statistical difference. It was also noted that male children responded significantly better to acetaminophen than ibuprofen (95% &#x000b1; 28 vs. 75 &#x000b1; 20). Although the most common abortive treatment is ibuprofen, the one that showed a better response was acetaminophen.<xref ref-type="bibr" rid="article-19421.r49">[49]</xref></p>
        <p>Studies compared the efficacy of oral paracetamol and oral ibuprofen for managing acute headaches in children with migraines without aura in India. There was no significant difference between the Paracetamol and Ibuprofen groups. This means that both paracetamol and ibuprofen are effective and safe for treating acute migraine attacks in children.<xref ref-type="bibr" rid="article-19421.r50">[50]</xref>&#x000a0;</p>
        <p>At the same time, ibuprofen and paracetamol are included in the World Health Organization Essential Medicines List (WHO EML) as the two analgesics for treating acute migraine attacks in children. Meta-analysis and assessments of evidence indicated that ibuprofen was superior to placebo for pain-free at 2 hours or pain relief at 2 hours, without difference in adverse events. At the same time, there were no differences between ibuprofen and paracetamol.<xref ref-type="bibr" rid="article-19421.r51">[51]</xref>&#x000a0;</p>
        <p>For mild headaches - acetaminophen with a dosage of 15 mg/kg every 4 to 6 hours; ibuprofen 10 mg/kg every 6 to 8 hours; naproxen 15 mg/kg every 4 to 6 hours.</p>
        <p>For moderate to severe headaches, adding a triptan may be necessary. Rizatriptan and sumatriptan, along with a combination of analgesics, have been FDA-approved for use in children. Based on clinical studies, sumatriptan is an effective and well-tolerated treatment when administered intravenously, subcutaneously, or orally. Sumatriptan also relieves photophobia, nausea, headache, and functional disability.<xref ref-type="bibr" rid="article-19421.r52">[52]</xref></p>
        <p>The protocol involves a non-opioid analgesic and dopamine receptor antagonist for emergency department treatment. Meanwhile, treatment with valproic acid is used as a continuous infusion. Administration of ketamine or propofol and peripheral nerve blocks could accelerate the treatment of pediatric migraine. Although there is an increasing variety of abortive treatments for pediatric migraine, there Is still a need for further research to validate these approaches.<xref ref-type="bibr" rid="article-19421.r37">[37]</xref></p>
        <p>A study compared pediatric migraine treatment efficacy in the emergency department before and after the implementation of a comprehensive migraine initiative in terms of the following: (1) standardized treatment protocol, (2) provider educational series, and (3) standardized physician documentation template. Results showed improvement in the efficacy and efficiency of migraine through a standardized treatment protocol, improved provider education, and ease of documentation.<xref ref-type="bibr" rid="article-19421.r53">[53]</xref>&#x000a0;</p>
        <p>
<bold>Recommended Preventive Treatment</bold>
</p>
        <p>Preventive treatment is needed during frequent migraine attacks, an impairment of the quality of life, severe accompanying or aura symptoms, and the failure of acute drug treatment. Below is a list of recommended pharmacological classes: (a) antidepressants, (b) antiepileptics, (c) antihistamines, (d) beta-adrenergic receptor blockers, and (e) calcium ion channel antagonists, as well as onabotulinum toxin A and nutraceuticals (butterbur).<xref ref-type="bibr" rid="article-19421.r54">[54]</xref>&#x000a0;</p>
        <p>If preventive medications are chosen, propranolol or nadolol (beta-blockers) can be given daily. Caution is advised in patients where beta-blockers are contraindicated, such as asthmatics, etc. Other medications that have proven useful include amitriptyline or nortriptyline, verapamil, antiepileptic agents (divalproex, topiramate, levetiracetam, and as used more in the past, phenobarbital and phenytoin), trazodone, and naproxen sodium.</p>
        <p>Studies are conducted to update evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population using the American Academy of Neurology 2011 process, as amended. Children with migraine receiving propranolol have at least a 50% reduction in headache frequency. Children receiving topiramate and cinnarizine have a decrease in headache frequency. Children with migraine receiving amitriptyline with cognitive behavioral therapy have a reduction in headache frequency. Other recommendations include counseling on lifestyle and behavioral factors that influence headache frequency and assessment and management of comorbidities related to persistent headaches.<xref ref-type="bibr" rid="article-19421.r55">[55]</xref> Moreover, previous studies also evaluated the efficacy and safety of topiramate (TPM) for migraine prophylaxis. They found that TPM could be considered a safe and effective drug in pediatric migraine prophylaxis.<xref ref-type="bibr" rid="article-19421.r56">[56]</xref>&#x000a0;In line with TPM, plasma calcitonin gene-related peptide (CGRP) level may be used as a therapeutic strategy since it is higher in patients needing migraine prevention and responsive to short-term topiramate treatment. CGRP can also differentiate migraine from non-migraine headaches. These findings are clinically significant among young children who cannot clearly identify their headache symptoms.<xref ref-type="bibr" rid="article-19421.r57">[57]</xref>&#x000a0;</p>
        <p>Another study found that serum magnesium levels were significantly low among children with migraine compared to those without migraine. Therefore, natural remedies such as&#x000a0;magnesium, CoQ-10, ginkgolide B butterbur, riboflavin, polyunsaturated fatty acids, and oral melatonin have also proven efficient and have a lower side effect profile.<xref ref-type="bibr" rid="article-19421.r58">[58]</xref>&#x000a0;</p>
        <p>Since most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, they most likely produce unfavorable side effects. Biological therapies blocking CGRP transmission are effective and better tolerated; however, they are expensive and may not influence brain dysfunctions upstream in the pathophysiological cascade of migraine, including premonitory and aura symptoms. On the other hand, biochemical and clinical studies mentioned a complementary treatment strategy that focuses on the metabolic facet of migraine pathophysiology. Findings revealed that riboflavin and coenzyme Q10 are effective for migraine prevention and quasi-devoid of adverse effects. Their response rates are similar to those of topiramate, propranolol, and CGRP/CGRPrec mAbs but are weaker for thioctic acid. Therefore, metabolic treatments of migraine demonstrated an effective, well-tolerated, inexpensive, and evidence-supported therapeutic option for migraine prophylaxis and may be used as the first treatment line among children.<xref ref-type="bibr" rid="article-19421.r59">[59]</xref>&#x000a0;</p>
        <p>Moreover, another study evaluated the efficacy of riboflavin treatment among pediatric patients. Findings revealed that children treated with riboflavin had reduced frequency of headaches, acute medication usage, and absences in school. Riboflavin prophylaxis also demonstrated a reduction in migraine intensity and duration. Therefore, riboflavin is recommended as a safe, inexpensive, and effective nutraceutical in pediatric migraine treatment.<xref ref-type="bibr" rid="article-19421.r60">[60]</xref></p>
        <p>Recent findings on Phytomedicines, or plant-based medicinal formulations, appear promising in identifying therapeutic targets in migraine as clinical and preclinical evidence of efficacy increases. Studied reviewed the mechanisms of action of the phytomedicines potentially useful for migraine, namely treatment-feverfew (Tanacetum parthenium), butterbur (Petasites hybridus), marijuana (Cannabis spp.), Saint John's Wort (Hypericum perforatum) and the Damask rose (Rosa &#x000d7; Damascena). Findings for feverfew are mixed; butterbur is effective with potential risks of hepatotoxicity related to preparation; marijuana has limited data and mostly did not show effectivity in migraine treatment; Saint John's Wort shows relevant physiological activity but is a hepatic enzyme inducer; the Damask rose when used in topical preparations did not show efficacy in one clinical trial.<xref ref-type="bibr" rid="article-19421.r61">[61]</xref></p>
        <p>Several studies showed that melatonin is effective for adult migraine prevention and has been used acutely for procedural pain in children. For acute treatment of pediatric migraine, both low and high doses of melatonin are involved with pain reduction; however, higher doses and napping after treatment predicted greater benefit.<xref ref-type="bibr" rid="article-19421.r62">[62]</xref></p>
        <p>Natural remedies such as&#x000a0;ginkgolide B butterbur, riboflavin, magnesium, CoQ-10, polyunsaturated fatty acids, and oral melatonin have also proven efficient and have a lower side effect profile.</p>
        <p>For&#x000a0;status migrainosus, consider intravenous or intramuscular administration of a drug like a valproate sodium (10 to 15 mg/kg), metoclopramide (5 to 10 mg), or prochlorperazine (2.5 to 5 mg).</p>
        <p>Previous studies mentioned that the majority of pediatric migraine patients are successfully discharged, and findings revealed that prochlorperazine appeared to be superior to metoclopramide in preventing a revisit. Diphenhydramineuse is associated with increased rates of return.<xref ref-type="bibr" rid="article-19421.r63">[63]</xref>&#x000a0;. Furthermore, ibuprofen, prochlorperazine, and other triptan medications are the most effective and safe treatments for the acute management of migraine and other benign headache disorders in the pediatric group.<xref ref-type="bibr" rid="article-19421.r64">[64]</xref></p>
        <p>A study assessed the efficacy and safety of a common monotherapy (intravenous [IV] metoclopramide) versus a combination strategy (adding IV ketorolac to metoclopramide) in children with acute treatment of migraine headaches in the emergency department. Findings revealed that the combination of IV metoclopramide and ketorolac failed to improve pain scores compared to metoclopramide monotherapy. Most of the patients were discharged with residual pain. The study also recommended counseling in terms of the following: (1) reassurance of prognosis to the parents; (2) trigger avoidance; (3) importance of lifestyle modification like proper sleep and water intake; and (4) importance of using analgesics at the early onset of headache.<xref ref-type="bibr" rid="article-19421.r65">[65]</xref></p>
        <p>However, some studies characterize the dystonic reactions to metoclopramide and prochlorperazine in children. It was revealed that dystonic reactions are rare among pediatric patients treated for acute headaches, but they are more common with prochlorperazine than metoclopramide.<xref ref-type="bibr" rid="article-19421.r66">[66]</xref>&#x000a0;</p>
        <p>Other studies mentioned that migraine is a response to a cerebral energy deficiency or oxidative stress levels that exceed antioxidant capacity. The ketogenic diet (KD), which causes the elevation of ketone bodies (KBs), targets cerebral metabolism that has recently shown great potential in preventing migraines. Ketone bodies are an alternative fuel source for the brain and are thus likely able to bypass some of the abnormalities in glucose metabolism and transport found in migraine. Recent findings revealed that KBs-D-&#x003b2;-hydroxybutyrate could potentially influence other pathways believed to be part of migraine pathophysiologies, such as mitochondrial functioning, oxidative stress, cerebral excitability, inflammation, and the gut microbiome. However, further studies are suggested to check whether the absence/restriction of dietary carbohydrates, the presence of KBs, or both, are significant for the migraine protective effects of KD.<xref ref-type="bibr" rid="article-19421.r67">[67]</xref>&#x000a0;</p>
        <p>Recent studies have been conducted to review the following treatment use in children, namely angiotensin antagonists such as candesartan, more selective 5-HT1F agonist like lasmiditan, new calcitonin gene-related peptide (CGRP) antibodies and antagonists, peripheral nerve blocks and botulinum toxin and electroceuticals which are therapeutic electric devices such as external trigeminal nerve stimulator (e-TNS), a non-invasive vagal nerve stimulator (nVNS), a single-pulse transcranial magnetic stimulator (sTMS) and a remote electrical neuromodulation device (REN). However, there is still a lack of evidence for their effectiveness in children.<xref ref-type="bibr" rid="article-19421.r68">[68]</xref>&#x000a0;&#x000a0;</p>
        <p>Counseling- Additional aspects of counseling include the following: (1) reassurance to the parents about the prognosis; (2) avoidance of triggers (3) the importance of lifestyle adjustments such as proper sleep and water intake, and (4) the importance of using analgesics early in the headache.</p>
        <p>Addressing these issues may reduce the frequency and severity of headaches. Inadequate sleep might be due to obstructive sleep apnea, among other possibilities.</p>
      </sec>
      <sec id="article-19421.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Several other health conditions may present, like a pediatric migraine.</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic daily headaches</p>
          </list-item>
          <list-item>
            <p>Brain tumors</p>
          </list-item>
          <list-item>
            <p>Vascular malformations</p>
          </list-item>
          <list-item>
            <p>Hydrocephalus</p>
          </list-item>
          <list-item>
            <p>Head trauma</p>
          </list-item>
          <list-item>
            <p>Mitochondriopathies</p>
          </list-item>
          <list-item>
            <p>Cluster headaches</p>
          </list-item>
        </list>
        <p>Headaches manifested in pseudotumor cerebri (pseudotumor; idiopathic intracranial hypertension) are nonspecific and are difficult to distinguish clinically from migraine. Children's headaches have a high predictive value for migraine versus nonmigraine headaches. Pseudotumor symptoms were similar to migraine except for the presence of diplopia in pseudotumor.<xref ref-type="bibr" rid="article-19421.r69">[69]</xref></p>
      </sec>
      <sec id="article-19421.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Early onset of migraine seems predictive for a less favorable outcome in later ages; however, follow-up studies are very limited and mostly with a short-term prospective period, of which the longest follow-up study is in a population of children with migraine under the age of 6. Some studies suggest that the onset of migraine at a very young age represents an unfavorable prognostic factor for the persistence of migraine at later ages. Some clinical features may change during the clinical course, and the active persistence of migraine may lead to an increase in allodynia.<xref ref-type="bibr" rid="article-19421.r70">[70]</xref>&#x000a0;</p>
        <p>Studies showed that cephalic cutaneous allodynia might appear in children and adolescents in the first six months of migraine onset. Contrary to adult studies, allodynia is not associated with migraine frequency or long disease duration but is significantly associated with migraine with aura, female gender, and awakening pain. A genetic tendency may be attributed to the appearance of allodynia in the pediatric age group.<xref ref-type="bibr" rid="article-19421.r71">[71]</xref></p>
        <p>In one of the published studies, 25% of patients stopped having migraines by the age of 25 years.<xref ref-type="bibr" rid="article-19421.r72">[72]</xref>&#x000a0;Another study reported about an 80% improvement in migraine by the age of 10 years.<xref ref-type="bibr" rid="article-19421.r73">[73]</xref> Lidegaard et al. reported a significant association between migraine and stroke in women aged 15 to 45 years who smoked or were on oral contraceptives.<xref ref-type="bibr" rid="article-19421.r74">[74]</xref></p>
      </sec>
      <sec id="article-19421.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Migraine complicated by prolonged neurologic signs has rarely been associated with a permanent neurologic deficit, and some of these cases may have been due to unrecognized metabolic diseases.</p>
      </sec>
      <sec id="article-19421.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>It is crucial to seek clinical help with symptoms to rule out any other secondary causes of headaches. Studies have reported improvement in migraines with weight loss in obese children.<xref ref-type="bibr" rid="article-19421.r75">[75]</xref>&#x000a0;Prenatal diagnosis may be available for&#x000a0;hemiplegic migraine, for which genetic counseling is, thus, advised.</p>
      </sec>
      <sec id="article-19421.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing migraine in the pediatric population&#x000a0;requires an interprofessional team that includes clinicians (MDs, DOs, NPs, and PAs), nurses, and pharmacists. It is imperative to do a thorough neurological and physical examination to rule out secondary headaches. If the child has migraine headaches, the non-pharmacological approach is considered the first line of treatment. Pharmacological therapy is the next step if avoiding triggers and non-pharmacological approaches do not resolve the headaches. Clinicians can coordinate with nurses on the initial non-pharmacological approach and then consult the pharmacist if drug therapy is deemed necessary; the pharmacist can assist in agent selection and dosing, perform medication reconciliation, and report any concerns that arise to the prescriber. In extreme cases, a headache specialist can also consult on the case. Interprofessional care will yield the best patient results. [Level 5]</p>
        <p>There&#x000a0;is insufficient evidence in the literature on interventional procedures such as botulinum toxin or nerve blocks in the pediatric migraine population.<xref ref-type="bibr" rid="article-19421.r76">[76]</xref><xref ref-type="bibr" rid="article-19421.r11">[11]</xref> There&#x000a0;is sufficient evidence indicating the combination of pharmacological and non-pharmacological approaches is the optimal approach. [Level 1]&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-19421.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19421&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19421">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/migraine-headaches/migraine-headache-in-childhood-migraine/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19421">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19421/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19421">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19421.s15">
        <title>References</title>
        <ref id="article-19421.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malinowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Varshney</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Deer</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Intrathecal drug delivery for pain management: recent advances and future developments.</article-title>
            <source>Expert Opin Drug Deliv</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>815</fpage>
            <page-range>815-822</page-range>
            <pub-id pub-id-type="pmid">31305165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szperka</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Headache in Children and Adolescents.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2021</year>
            <month>Jun</month>
            <day>01</day>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>703</fpage>
            <page-range>703-731</page-range>
            <pub-id pub-id-type="pmid">34048400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Brien</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Kabbouche</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kacperski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hershey</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Treatment of pediatric migraine.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>326</fpage>
            <pub-id pub-id-type="pmid">25617222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rothner</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Migraine Variants in Children.</article-title>
            <source>Pediatr Ann</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>e50</fpage>
            <page-range>e50-e54</page-range>
            <pub-id pub-id-type="pmid">29446794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greene</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Pediatric Migraine: An Update.</article-title>
            <source>Neurol Clin</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>815</fpage>
            <page-range>815-833</page-range>
            <pub-id pub-id-type="pmid">31563234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oskoui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Holler-Managan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Potrebic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Billinghurst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hershey</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Licking</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sowell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Victorio</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gersz</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Leininger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zanitsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yonker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>1158</fpage>
            <page-range>1158-1173</page-range>
            <pub-id pub-id-type="pmid">31529481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kries</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Straube</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heinen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Landgraf</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Obermeier</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ruscheweyh</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Age- and sex-specific first health care use for migraine in 2016 in children and adolescents from prospectively collected health insurance data in Germany.</article-title>
            <source>Cephalalgia</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>9</issue>
            <fpage>1156</fpage>
            <page-range>1156-1163</page-range>
            <pub-id pub-id-type="pmid">30974953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kandt</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Headache and acute illness in children.</article-title>
            <source>J Child Neurol</source>
            <year>1987</year>
            <month>Jan</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-7</page-range>
            <pub-id pub-id-type="pmid">3624825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziegler</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Hur</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Bouchard</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hassanein</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Barter</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Migraine in twins raised together and apart.</article-title>
            <source>Headache</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>417</fpage>
            <page-range>417-22</page-range>
            <pub-id pub-id-type="pmid">9664744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eidlitz-Markus</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zeharia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Younger Age of Migraine Onset in Children Than Their Parents: A Retrospective Cohort Study.</article-title>
            <source>J Child Neurol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-97</page-range>
            <pub-id pub-id-type="pmid">29246099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chakravarthy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Neurostimulation for Intractable Chronic Pain.</article-title>
            <source>Brain Sci</source>
            <year>2019</year>
            <month>Jan</month>
            <day>24</day>
            <volume>9</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30682776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hershey</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>An update on acute and preventive treatments for migraine in children and adolescents.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1017</fpage>
            <page-range>1017-1027</page-range>
            <pub-id pub-id-type="pmid">32700569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burish</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rozen</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Trigeminal Autonomic Cephalalgias.</article-title>
            <source>Neurol Clin</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>847</fpage>
            <page-range>847-869</page-range>
            <pub-id pub-id-type="pmid">31563236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Millman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Migraine headache in children.</article-title>
            <source>Clin Evid</source>
            <year>2006</year>
            <month>Jun</month>
            <issue>15</issue>
            <fpage>469</fpage>
            <page-range>469-75</page-range>
            <pub-id pub-id-type="pmid">16973019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takeshima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Komori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stretton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Treuer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature.</article-title>
            <source>J Headache Pain</source>
            <year>2019</year>
            <month>Dec</month>
            <day>05</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <pub-id pub-id-type="pmid">31805851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavkovic</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Kothare</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Migraine and Sleep in Children: A Bidirectional Relationship.</article-title>
            <source>Pediatr Neurol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>109</volume>
            <fpage>20</fpage>
            <page-range>20-27</page-range>
            <pub-id pub-id-type="pmid">32165029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strang-Karlsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alenius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>N&#x000e4;s&#x000e4;nen-Gilmore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nurhonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haaramo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Evensen</surname>
                <given-names>KAI</given-names>
              </name>
              <name>
                <surname>V&#x000e4;&#x000e4;r&#x000e4;sm&#x000e4;ki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gissler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hovi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kajantie</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Migraine in children and adults born preterm: A nationwide register linkage study.</article-title>
            <source>Cephalalgia</source>
            <year>2021</year>
            <month>May</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>677</fpage>
            <page-range>677-689</page-range>
            <pub-id pub-id-type="pmid">33297743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nesterovsky</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Zavadenko</surname>
                <given-names>NN</given-names>
              </name>
            </person-group>
            <article-title>[Comorbidity of migraine and epilepsy in childhood].</article-title>
            <source>Zh Nevrol Psikhiatr Im S S Korsakova</source>
            <year>2018</year>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>100</fpage>
            <page-range>100-106</page-range>
            <pub-id pub-id-type="pmid">29863702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kutuk</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Tufan</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Guler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yalin</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Altintas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bag</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Uluduz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Toros</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aytan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kutuk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ozge</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Migraine and associated comorbidities are three times more frequent in children with ADHD and their mothers.</article-title>
            <source>Brain Dev</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>10</issue>
            <fpage>857</fpage>
            <page-range>857-864</page-range>
            <pub-id pub-id-type="pmid">29921473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Faedda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Natalucci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bellini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salvi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Verdecchia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cerutti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arruda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guidetti</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The role of attachment insecurity in the emergence of anxiety symptoms in children and adolescents with migraine: an empirical study.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <pub-id pub-id-type="pmid">28560542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forcelini</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>IFD</given-names>
              </name>
              <name>
                <surname>Brackmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bernardon</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Corbellini</surname>
                <given-names>APZ</given-names>
              </name>
              <name>
                <surname>Perin</surname>
                <given-names>BV</given-names>
              </name>
            </person-group>
            <article-title>The influence of allergic rhinoconjunctivitis on migraine disability in children.</article-title>
            <source>Arq Neuropsiquiatr</source>
            <year>2019</year>
            <month>Jul</month>
            <day>15</day>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>418</fpage>
            <page-range>418-423</page-range>
            <pub-id pub-id-type="pmid">31314844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Benn</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Koth</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Migraine is common in patients with sarcoidosis.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>14</issue>
            <fpage>2079</fpage>
            <page-range>2079-2082</page-range>
            <pub-id pub-id-type="pmid">29580067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Spare</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Erenumab in the treatment of migraine.</article-title>
            <source>Pain Manag</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>415</fpage>
            <page-range>415-426</page-range>
            <pub-id pub-id-type="pmid">30235976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mathews</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Anatomy, Head and Neck, Cricoid Cartilage</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">30969643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Al Khalili</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ly</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <chapter-title>Cervicogenic Headache</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>10</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">29939639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazanasmaz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Calik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000fc;m&#x000fc;&#x0015f;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koyuncu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kazanasmaz</surname>
                <given-names>&#x000d6;</given-names>
              </name>
            </person-group>
            <article-title>Investigation of the plasma copeptin level in cases with childhood migraine.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>952</fpage>
            <page-range>952-959</page-range>
            <pub-id pub-id-type="pmid">33295228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stokoe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khaira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amoozegar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>GABA and glutamate in pediatric migraine.</article-title>
            <source>Pain</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>162</volume>
            <issue>1</issue>
            <fpage>300</fpage>
            <page-range>300-308</page-range>
            <pub-id pub-id-type="pmid">33326202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nita</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Teleanu</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Bajenaru</surname>
                <given-names>OA</given-names>
              </name>
            </person-group>
            <article-title>The Role of Polysomnography in Identifying Sleep Disorders in Children with Migraine.</article-title>
            <source>J Med Life</source>
            <year>2020</year>
            <season>Jan-Mar</season>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-67</page-range>
            <pub-id pub-id-type="pmid">32341703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziplow</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Psychiatric Comorbidities of Migraine in Children and Adolescents.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2021</year>
            <month>Nov</month>
            <day>11</day>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>69</fpage>
            <pub-id pub-id-type="pmid">34766216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Y&#x00131;lmaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000d6;zl&#x000fc;</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kurt</surname>
                <given-names>AN&#x000c7;</given-names>
              </name>
            </person-group>
            <article-title>Ambulatory blood pressure abnormalities in children with migraine.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>11</issue>
            <fpage>2157</fpage>
            <page-range>2157-2162</page-range>
            <pub-id pub-id-type="pmid">32556954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landgraf</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Biebl</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Langhagen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hannibal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Eggert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vill</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gerstl</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>von Kries</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Straube</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heinen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Children with migraine: Provocation of headache via pressure to myofascial trigger points in the trapezius muscle? - A prospective controlled observational study.</article-title>
            <source>Eur J Pain</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>385</fpage>
            <page-range>385-392</page-range>
            <pub-id pub-id-type="pmid">28952174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Al Khalili</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Asuncion</surname>
                <given-names>RMD</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Migraine Headache in Childhood</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">32491745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Al Khalili</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <chapter-title>Retinal Migraine Headache</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29939547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eidlitz-Markus</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haimi-Cohen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeharia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vomiting and migraine-related clinical parameters in pediatric migraine.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>899</fpage>
            <page-range>899-907</page-range>
            <pub-id pub-id-type="pmid">28480554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowling</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Noetzel</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rodeghier</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Hirtz</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Ichord</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Roach</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Kirkham</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Casella</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>DeBaun</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction.</article-title>
            <source>J Pediatr</source>
            <year>2014</year>
            <month>May</month>
            <volume>164</volume>
            <issue>5</issue>
            <fpage>1175</fpage>
            <page-range>1175-1180.e1</page-range>
            <pub-id pub-id-type="pmid">24529619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r36">
          <label>36</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tubben</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <chapter-title>Epidural Blood Patch</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">29493961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kinast</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lueders</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rothner</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Erenberg</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Benign focal epileptiform discharges in childhood migraine (BFEDC).</article-title>
            <source>Neurology</source>
            <year>1982</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>11</issue>
            <fpage>1309</fpage>
            <page-range>1309-11</page-range>
            <pub-id pub-id-type="pmid">6813763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orr</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Kabbouche</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Kacperski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Hershey</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Paediatric migraine: evidence-based management and future directions.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>515</fpage>
            <page-range>515-527</page-range>
            <pub-id pub-id-type="pmid">30038237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yaghini</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hoseini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghazavi</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Mansouri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nasiri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moosavian</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Salehi</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>A Comparative Study on the Efficacy of Coenzyme Q10 and Amitriptyline in the Prophylactic Treatment of Migraine Headaches in Children: A Randomized Controlled Trial.</article-title>
            <source>Adv Biomed Res</source>
            <year>2022</year>
            <volume>11</volume>
            <fpage>43</fpage>
            <pub-id pub-id-type="pmid">35814300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orr</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>The Evidence for the Role of Nutraceuticals in the Management of Pediatric Migraine: a Review.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Apr</month>
            <day>04</day>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">29619575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tekin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Edem</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effects and side effects of migraine prophylaxis in children.</article-title>
            <source>Pediatr Int</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>e15094</fpage>
            <pub-id pub-id-type="pmid">34905279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbanti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grazzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Egeo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for acute migraines in children and adolescents.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>455</fpage>
            <page-range>455-463</page-range>
            <pub-id pub-id-type="pmid">30526161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yonker</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>McVige</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeitlin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11&#x02009;years, with an open-label extension.</article-title>
            <source>Headache</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>9</issue>
            <fpage>1207</fpage>
            <page-range>1207-1217</page-range>
            <pub-id pub-id-type="pmid">36286602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKeage</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older.</article-title>
            <source>Paediatr Drugs</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">26747634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Drugs for Acute Attack of Pediatric Migraine: A Network Meta-analysis of Randomized Controlled Trials.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>195</volume>
            <fpage>105853</fpage>
            <pub-id pub-id-type="pmid">32464520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Billinghurst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Linsdell</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vandermeer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Crumley</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Durec</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klassen</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Hartling</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Drugs for the acute treatment of migraine in children and adolescents.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Apr</month>
            <day>19</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>CD005220</fpage>
            <pub-id pub-id-type="pmid">27091010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Surani</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Yousuf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anjum</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Topiramate For Migraine Prophylaxis Among Children Aged 5 To 15 Years.</article-title>
            <source>J Ayub Med Coll Abbottabad</source>
            <year>2021</year>
            <season>Jul-Sep</season>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>480</fpage>
            <page-range>480-483</page-range>
            <pub-id pub-id-type="pmid">34487661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aydin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bucak</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Geyik</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B12 and folic acid levels in pediatric migraine patients.</article-title>
            <source>Acta Neurol Belg</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>121</volume>
            <issue>6</issue>
            <fpage>1741</fpage>
            <page-range>1741-1744</page-range>
            <pub-id pub-id-type="pmid">32955709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Genizi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lahoud</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Migraine abortive treatment in children and adolescents in Israel.</article-title>
            <source>Sci Rep</source>
            <year>2022</year>
            <month>May</month>
            <day>06</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>7418</fpage>
            <pub-id pub-id-type="pmid">35523834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavithra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Behera</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Juneja</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Paracetamol versus Ibuprofen for the Acute Treatment of Migraine Headache in Children: A Blinded Randomized Controlled Trial.</article-title>
            <source>Indian J Pediatr</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>87</volume>
            <issue>10</issue>
            <fpage>781</fpage>
            <page-range>781-786</page-range>
            <pub-id pub-id-type="pmid">32451827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeric</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Surjan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jelicic Kadic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Puljak</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Treatment of acute migraine attacks in children with analgesics on the World Health Organization Essential Medicines List: A systematic review and GRADE evidence synthesis.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>1592</fpage>
            <page-range>1592-1607</page-range>
            <pub-id pub-id-type="pmid">29034788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r52">
          <label>52</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Brar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hosseini</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Sumatriptan</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29262214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skora</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Worden</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Oakley</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive Migraine Initiative in the Pediatric Emergency Department Improves Treatment Outcomes.</article-title>
            <source>J Child Neurol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-241</page-range>
            <pub-id pub-id-type="pmid">31805806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tajti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szok</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cs&#x000e1;ti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>V&#x000e9;csei</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">26695061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oskoui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Billinghurst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Potrebic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gersz</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Holler-Managan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Leininger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Licking</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sowell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cristina Victorio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yonker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zanitsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hershey</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Headache</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>1144</fpage>
            <page-range>1144-1157</page-range>
            <pub-id pub-id-type="pmid">31529477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sarraf Yazd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sohrevardi</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Topiramate Alone and Topiramate Plus Vitamin D3 in the Prophylaxis of Pediatric Migraine: A Randomized Clinical Trial.</article-title>
            <source>Iran J Child Neurol</source>
            <year>2020</year>
            <season>Fall</season>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>77</fpage>
            <page-range>77-86</page-range>
            <pub-id pub-id-type="pmid">33193786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fan</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chiou</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Plasma Calcitonin Gene-Related Peptide: A Potential Biomarker for Diagnosis and Therapeutic Responses in Pediatric Migraine.</article-title>
            <source>Front Neurol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">30733702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhurat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Premkumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manokaran</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Serum Magnesium Levels in Children With and Without Migraine: A Cross-Sectional Study.</article-title>
            <source>Indian Pediatr</source>
            <year>2022</year>
            <month>Aug</month>
            <day>15</day>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>623</fpage>
            <page-range>623-625</page-range>
            <pub-id pub-id-type="pmid">35751375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lisicki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Metabolic treatments of migraine.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>295</fpage>
            <page-range>295-302</page-range>
            <pub-id pub-id-type="pmid">32067520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Qubty</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Retrospective Observational Study on Riboflavin Prophylaxis in Child and Adolescent Migraine.</article-title>
            <source>Pediatr Neurol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>114</volume>
            <fpage>5</fpage>
            <page-range>5-8</page-range>
            <pub-id pub-id-type="pmid">33189027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajapakse</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Phytomedicines in the Treatment of Migraine.</article-title>
            <source>CNS Drugs</source>
            <year>2019</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>399</fpage>
            <page-range>399-415</page-range>
            <pub-id pub-id-type="pmid">30627973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gelfand</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Qubty</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>IE</given-names>
              </name>
            </person-group>
            <article-title>Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.</article-title>
            <source>Headache</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>60</volume>
            <issue>8</issue>
            <fpage>1712</fpage>
            <page-range>1712-1721</page-range>
            <pub-id pub-id-type="pmid">32965037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bachur</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Monuteaux</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Neuman</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>A comparison of acute treatment regimens for migraine in the emergency department.</article-title>
            <source>Pediatrics</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>135</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-8</page-range>
            <pub-id pub-id-type="pmid">25624377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patniyot</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review.</article-title>
            <source>Headache</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-70</page-range>
            <pub-id pub-id-type="pmid">26790849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richer</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Rosychuk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>A randomized trial of ketorolac and metoclopramide for migraine in the emergency department.</article-title>
            <source>Headache</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>681</fpage>
            <page-range>681-689</page-range>
            <pub-id pub-id-type="pmid">35670115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sogawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cleves</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Acute Dystonic Reactions in Children Treated for Headache With Prochlorperazine or Metoclopramide.</article-title>
            <source>Pediatr Neurol</source>
            <year>2020</year>
            <month>May</month>
            <volume>106</volume>
            <fpage>63</fpage>
            <page-range>63-64</page-range>
            <pub-id pub-id-type="pmid">32098684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gross</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Klement</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>D'Agostino</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention.</article-title>
            <source>Nutrients</source>
            <year>2019</year>
            <month>Apr</month>
            <day>10</day>
            <volume>11</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30974836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loh</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Whitehouse</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Howells</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>What is new in migraine management in children and young people?</article-title>
            <source>Arch Dis Child</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>107</volume>
            <issue>12</issue>
            <fpage>1067</fpage>
            <page-range>1067-1072</page-range>
            <pub-id pub-id-type="pmid">35190383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Edelman</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Stafstrom</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Evidence of Diplopia in Children's Headache Drawings Helps to Differentiate Pseudotumor Cerebri From Migraine.</article-title>
            <source>Pediatr Neurol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>79</volume>
            <fpage>40</fpage>
            <page-range>40-44</page-range>
            <pub-id pub-id-type="pmid">29413638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchese</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rocchitelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Nardello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mangano</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Vanadia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mangano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brighina</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Raieli</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Migraine in children under 6 years of age: A long-term follow-up study.</article-title>
            <source>Eur J Paediatr Neurol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>27</volume>
            <fpage>67</fpage>
            <page-range>67-71</page-range>
            <pub-id pub-id-type="pmid">32334992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levinsky</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeharia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eidlitz-Markus</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cephalic cutaneous allodynia in children and adolescents with migraine of short duration: A retrospective cohort study.</article-title>
            <source>Cephalalgia</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-67</page-range>
            <pub-id pub-id-type="pmid">29732930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bille</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>A 40-year follow-up of school children with migraine.</article-title>
            <source>Cephalalgia</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>488</fpage>
            <page-range>488-91; discussion 487</page-range>
            <pub-id pub-id-type="pmid">9209767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dooley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bagnell</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The prognosis and treatment of headaches in children--a ten year follow-up.</article-title>
            <source>Can J Neurol Sci</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-9</page-range>
            <pub-id pub-id-type="pmid">7750073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lidegaard</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease.</article-title>
            <source>Br J Obstet Gynaecol</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>102</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-9</page-range>
            <pub-id pub-id-type="pmid">7756208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verrotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carotenuto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altieri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tozzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Belcastro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guastaferro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ciuti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiarelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Agostinelli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Migraine and obesity: metabolic parameters and response to a weight loss programme.</article-title>
            <source>Pediatr Obes</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>220</fpage>
            <page-range>220-5</page-range>
            <pub-id pub-id-type="pmid">24990114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19421.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deer</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Grider</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lamer</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Falowski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Provenzano</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carayannopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Harned</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hagedorn</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bolash</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Arle</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kapural</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Amirdelfan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liem</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Malinowski</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Bendel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aiyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Valimahomed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Antony</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Al-Kaisy</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Christelis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rosenquist</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mekhail</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Literature Review of Spine Neurostimulation Therapies for the Treatment of Pain.</article-title>
            <source>Pain Med</source>
            <year>2020</year>
            <month>Nov</month>
            <day>07</day>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>1421</fpage>
            <page-range>1421-1432</page-range>
            <pub-id pub-id-type="pmid">32034422</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
